Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Antengene And XtalPi Announce AI-Driven R&D Collaboration

Multi-year collaboration has the potential to accelerate Antengene’s drug discovery engine and novel candidate identification and evaluation

Antengene Corporation Limited, a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases and XtalPi Inc, a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate, announced a long-term R&D collaboration.

Recommended AI News: Enjinstarter to Launch 20 IDOs in December 2021 

PREDICTIONS-SERIES-2022

Under terms of the agreement, XtalPi will utilize its integrated artificial intelligence (AI) research and development (R&D) platform comprised of proprietary cloud-supercomputer-powered in silico tools and its highly efficient wet lab to support Antengene’s drug discovery and development programs.

Related Posts
1 of 29,057

“This collaboration is in keeping with Antengene’s mission of bringing best-in-class/first-in-class medicines for people with cancer and other life-threatening diseases. We are very excited about the opportunity to accelerate the pace of candidate identification, selection and preclinical evaluation by working with XtalPi to conduct in silico compound synthesis and testing. We believe this technology will allow us to explore a wider chemical space which could be especially valuable for completely new targets.”said Dr. Jay Mei, Founder and CEO of Antengene.

Recommended AI News: Crypto-collateralized Lending Offered by PayBito Gains Market Favor

 “The excellent cooperation and potential for a long-term collaboration between XtalPi and Antengene is based on the good trust established by both parties. I believe that XtalPi’s pioneering, AI-driven technology can help our partner, Antengene, develop new therapies at a pace and scale beyond traditional alternatives. The positive scientific collaboration between the scientists at XtalPi and Antengene sets the stage for a “win-win relationship” that can provide a mutual benefit to both parties” said Dr. Ma Jian, CEO of XtalPi.

Recommended AI News: Mobilum Technologies Signs Agreement To Integrate Off-Ramp Services Into The Ledger Live Platform, Gateway For Digital Assets & Web3

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.